Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 3/20 | 0.31 |
| ▸ | CDK8 | P49336 | 3/20 | 0.31 |
| ▸ | HASPIN | Q8TF76 | 3/20 | 0.31 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424458 | 0.82 | OPRM1 (0.38) | OPRM1OPRD1OPRK1JAK1 | |
| SCHEMBL12666963 | 0.80 | DRD2 (0.34) | OPRM1OPRK1DRD2 | |
| SCHEMBL23514873 | 0.78 | OPRM1 (0.38) | OPRM1OPRD1OPRK1 | |
| SCHEMBL12384770 | 0.77 | OPRM1 (0.35) | OPRM1OPRD1OPRK1JAK1 | |
| SCHEMBL12424278 | 0.77 | OPRM1 (0.38) | OPRM1OPRD1OPRK1JAK1 | |
| SCHEMBL26961724 | 0.76 | FFAR3 (0.46) | OPRM1OPRD1OPRK1JAK1DRD2 | |
| SCHEMBL23073856 | 0.75 | JAK1 (0.35) | OPRM1OPRD1OPRK1JAK1 | |
| SCHEMBL8292668 | 0.75 | OPRM1 (0.35) | OPRM1OPRD1OPRK1JAK1 | |
| SCHEMBL24342357 | 0.75 | OPRM1 (0.38) | OPRM1OPRD1OPRK1JAK1DRD2 | |
| SCHEMBL12409505 | 0.75 | DRD2 (0.32) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| EP-4384503-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
| WO-2023018781-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018781-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022261777-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER | REPARE THERAPEUTICS INC. (CA) | 2022-12-22 | — | — | WO | disclosed |
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2022-06-16 | — | — | US | disclosed |
| WO-2021119523-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | OPRM1 793/4885OPRD1 457/4885OPRK1 667/4885 |
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | OPRM1 4438/4885OPRD1 3974/4885OPRK1 3428/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | OPRM1 2907/4885OPRD1 2485/4885OPRK1 1823/4885 |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | OPRM1 2907/4885OPRD1 2485/4885OPRK1 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.